Last reviewed · How we verify
phenobarbitone — Competitive Intelligence Brief
phase 1
Nuclear receptor subfamily 1 group I member 2, Nuclear receptor subfamily 1 group I member 3, GABA-A receptor alpha-1/beta-2/gamma-2
Neuroscience
Small molecule
Live · refreshed every 30 min
Target snapshot
phenobarbitone (phenobarbitone) — Institute of Child Health.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| phenobarbitone TARGET | phenobarbitone | Institute of Child Health | phase 1 | Nuclear receptor subfamily 1 group I member 2, Nuclear receptor subfamily 1 group I member 3, GABA-A receptor alpha-1/beta-2/gamma-2 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- phenobarbitone CI watch — RSS
- phenobarbitone CI watch — Atom
- phenobarbitone CI watch — JSON
- phenobarbitone alone — RSS
Cite this brief
Drug Landscape (2026). phenobarbitone — Competitive Intelligence Brief. https://druglandscape.com/ci/phenobarbitone. Accessed 2026-06-10.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing